Provided By GlobeNewswire
Last update: Dec 4, 2025
New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the “MOU”) with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market.
Read more at globenewswire.comNASDAQ:MENS (12/5/2025, 8:00:00 PM)
29.2
+0.01 (+0.03%)
Find more stocks in the Stock Screener


